Article
Multidisciplinary Sciences
Stella Pearson, Anthony D. Whetton, Andrew Pierce
Summary: Despite advances in precision medicine targeted therapies for cancer, the development of curative treatments remains challenging due to drug resistance in cancer stem cells. Chronic myeloid leukemia is a model for studying cancer stem cells and although targeted therapies have been developed, drug resistance remains a problem. New treatment strategies are needed to target other components within leukemia stem cells, either alone or in combination with existing therapies.
Article
Gastroenterology & Hepatology
Koelina Ganguly, Rakesh Bhatia, Sanchita Rauth, Andrew Kisling, Pranita Atri, Christopher Thompson, Raghupathy Vengoji, Shiv Ram Krishn, Dhananjay Shinde, Vinai Thomas, Sukhwinder Kaur, Kavita Mallya, Jesse L. Cox, Sushil Kumar, Surinder K. Batra
Summary: The study reveals that MUC5AC promotes gemcitabine resistance in pancreatic cancer cells by affecting glutamine metabolism and nucleotide biosynthesis. Depletion of MUC5AC and deprivation of glutamine can enhance sensitivity of pancreatic cancer cells to gemcitabine. Dual-targeting therapy against MUC5AC, beta-catenin, and glutamine metabolism can overcome gemcitabine resistance in pancreatic cancer.
Article
Oncology
Wei Zhang, Yanwei Zhang, Wensheng Zhou, Fangfei Qian, Minjuan Hu, Ya Chen, Jun Lu, Yuqing Lou, Baohui Han
Summary: PlGF plays a role in promoting cell proliferation and glycolysis in LUAD cells through activating the Wnt/β-catenin pathway. Knockdown of PlGF significantly inhibits these processes.
CANCER CELL INTERNATIONAL
(2021)
Article
Nutrition & Dietetics
Jun Chen, Zhiguang Duan, Yannan Liu, Rongzhan Fu, Chenhui Zhu
Summary: This study found that ginsenoside Rh4 inhibits the metastasis of esophageal squamous cell carcinoma (ESCC) by regulating the Wnt/beta-catenin signaling pathway and the level of c-Myc. In vitro and in vivo experiments confirmed the inhibitory effect of Rh4 on ESCC metastasis.
Article
Cell Biology
Guoxi Zhang, Junrong Zou, Jinglin Shi, Biao Qian, Kaiyang Qiu, Quanliang Liu, Tianpeng Xie, Zhihua He, Hui Xu, Yunfeng Liao, Yuting Wu, Yanmin Li, Guancheng Xiao, Yuanhu Yuan, Rihai Xiao, Gengqing Wu, Xiaofeng Zou
Summary: UBA2 expression is higher in clear cell renal cell carcinoma compared to normal tissues, and is significantly related to tumor size, Fuhrman grade, and tumor stage. Knockdown of UBA2 inhibits ccRCC cell growth, promotes apoptosis, and decreases key enzyme abundance of the SUMO modification system. Targeting UBA2 may have therapeutic potential against ccRCC.
CELL DEATH & DISEASE
(2021)
Article
Biochemistry & Molecular Biology
Hyeon Hee Kwon, Chi-Hoon Ahn, Hyo-Jung Lee, Deok Yong Sim, Ji Eon Park, Su-Yeon Park, Bonglee Kim, Bum-Sang Shim, Sung-Hoon Kim
Summary: This study found that Brassinin induces apoptosis in prostate cancer cells through ROS-mediated inhibition of SIRT1, c-Myc, beta-catenin, and glycolysis proteins.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biotechnology & Applied Microbiology
Ning Wang, Shuang-Shuang Dong, Chun-Lin Wu, Ying Wang, Lian Meng, Yan Ren, Xiao-Bin Cui, Man Li, Yan Qi
Summary: Pulmonary PNETs without thoracic wall involvement are extremely rare and aggressive. This case report of a 41-year-old woman with pulmonary PNET includes histopathological, immunohistochemical, and molecular pathological examinations, along with a literature review on primary pulmonary PNETs.
ONCOTARGETS AND THERAPY
(2021)
Article
Oncology
Himanshu Singh Saroha, Rohith Kumar Guddeti, Jasmine P. Jacob, Kiran Kumar Pulukuri, Prashanthi Karyala, Suresh B. Pakala
Summary: The expression of MORC2 is positively correlated with beta-catenin in breast cancer, and overexpression of MORC2 increases beta-catenin and its target genes. The target gene of beta-catenin, c-Myc, regulates the MORC2-beta-catenin signaling axis through a feedback mechanism. MORC2 regulates beta-catenin expression and function by modulating AKT phosphorylation, promoting proliferation and migration of breast cancer cells.
Article
Obstetrics & Gynecology
Xiang Feng, Lina Zhang, Yanling Tan, Aihua Feng, Fei Luo, Mengfan Xu, Hong Ye, Hongyu Zhu, Peng Zhou, Hua Li
Summary: PNET during pregnancy is a rare and complex condition that requires an individualized treatment plan based on gestational age. Timely surgical treatment can significantly prolong patient survival, but may also result in fetal loss and the inability to continue pregnancy.
BMC PREGNANCY AND CHILDBIRTH
(2021)
Article
Oncology
Lijun An, Huiyuan Gong, Xiaojing Yu, Wangming Zhang, Xiaohua Liu, Xiaomin Yang, Liping Shu, Jielin Liu, Liuqi Yang
Summary: This study found that MAL2 is significantly upregulated in breast cancer tissues and is associated with poor prognosis. Functional experiments showed that MAL2 knockdown can inhibit migration and invasion of breast cancer cells, increase apoptosis, and reduce metastatic capacity. Mechanistically, MAL2 interacts with beta-catenin in breast cancer cells and regulates the EMT and beta-catenin/c-Myc axis to promote tumor progression.
CANCER CELL INTERNATIONAL
(2023)
Article
Oncology
Colin J. Daniel, Carl Pelz, Xiaoyan Wang, Michael W. Munks, Aaron Ko, Dhaarini Murugan, Sarah A. Byers, Eleonora Juarez, Karyn L. Taylor, Guang Fan, Lisa M. Coussens, Jason M. Link, Rosalie C. Sears
Summary: This study highlights the importance of regulated phosphorylation of MYC at T58 and S62 in T-cell transformation, and reveals differential effects of MYC lacking phosphorylation on T-cell development and lymphomagenesis.
MOLECULAR CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Ryosuke Wakabayashi, Yasunao Hattori, Shigekuni Hosogi, Yuki Toda, Kazuyuki Takata, Eishi Ashihara
Summary: Compound 31 was identified as an inhibitor of the Wnt/beta-catenin pathway, showing potential as a novel anti-AML agent by suppressing TCF activity, reducing AML cell proliferation, inducing apoptosis, and synergistically inhibiting cell growth when combined with idarubicin.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Keisuke Omori, Shohei Otani, Yuki Date, Tomoya Ueno, Tomoko Ito, Masahiro Umeda, Kosei Ito
Summary: Osteosarcoma is a disease in humans characterized by TP53 mutations. In mice, loss of p53 triggers OS development, and osteoprogenitor-specific p53-deleted mice are widely used to study the process of osteosarcomagenesis. However, the molecular mechanisms underlying the initiation or progression of OS following or parallel to p53 inactivation remain largely unknown. This study reveals a novel tumor suppressive mechanism mediated by C/ebp alpha in p53-deficient osteosarcomagenesis, highlighting the importance of the Runx-Myc oncogenic axis as a therapeutic target for OS.
Article
Oncology
Adnan Shami Shah, Xiaofu Cao, Andrew C. White, Jeremy M. Baskin
Summary: The study identifies PLEKHA4 as a crucial factor for melanoma proliferation and survival, demonstrating its essential role in Wnt/beta-catenin signaling. Knocking down PLEKHA4 attenuated tumor growth in both BRAF- and NRAS-mutant melanoma models, with an additive effect when combined with the clinically used inhibitor encorafenib in the BRAF-mutant model. As an E3 ubiquitin ligase regulator, PLEKHA4 presents promising opportunities for targeting in melanoma therapy.
Review
Cardiac & Cardiovascular Systems
Jingjing Wang, Jing Li, Xiao Zhang, Xiaobo Zhang, Yueyong Xiao
Summary: This paper presents a rare case of peripheral primitive neuroectodermal tumor originating in the pericardium, which was successfully treated with surgical resection and postoperative chemotherapy with 7 years of disease-free follow-up, but recurred at 7 years after treatment.
BMC CARDIOVASCULAR DISORDERS
(2021)